BioTuesdays

Tag - BTIG

Markets

BTIG starts Oncternal at buy; PT $5

BTIG launched coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and $5 price target. The stock closed at $1.73 on Feb. 23. Oncternal is a clinical-stage biotechnology company focused on a diverse...

February 24, 2022
Zosano Logo
Markets

BTIG cuts Zosano to neutral from buy; removes PT

BTIG downgraded Zosano Pharma (NASDAQ:ZSAN) to “neutral” from “buy” and removed its price target after the FDA refused to accept the company’s NDA resubmission for M207 to treat acute migraine. Shares of Zosano, which...

February 23, 2022
Aerovate Therapeutics
Markets

BTIG starts Aerovate Therapeutics at buy; PT $24

BTIG launched coverage of Aerovate Therapeutics (NASDAQ:AVTE) with a “buy” rating and $24 price target. The stock closed at $9.40 on Feb. 10. Aerovate is focused exclusively on developing a dry powder inhaled...

February 11, 2022
acutus logo
Markets

BTIG cuts Acutus Medical to neutral from buy

BTIG downgraded Acutus Medical (NASDAQ:AFIB) to “neutral” from “buy” and removed its price target, citing a forecast of flat sales in 2022, among other things. The stock closed at $2.46 on Jan. 19. Acutus is a cardiac...

January 20, 2022
Pear Therapeutics
Markets

BTIG starts Pear Therapeutics at buy; PT $12

BTIG initiated coverage of Pear Therapeutics (NASDAQ:PEAR) with a “buy” rating and $12 price target. The stock closed at $6.20 on Dec. 31.  Pear is a leader in prescription digital therapeutics (PDTs), with three...

January 3, 2022
Freeline Therapeutics
Markets

BTIG starts Freeline Therapeutics at buy; PT $10

BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...

November 29, 2021
Mdx Health
Markets

BTIG starts MDx Health at buy; PT $15

BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...

November 29, 2021
Aura Biosciences
Markets

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

November 23, 2021
Lensar
Markets

BTIG starts LENSAR at buy; PT $15

BTIG launched coverage of LENSAR (NASDAQ:LNSR) with a “buy” rating and $15 price target. The stock closed at $7.10 on Nov. 19. LENSAR is a small-cap technology play on the fast growing laser cataract surgery market. By...

November 22, 2021